Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.

AIM The effects of pioglitazone hydrochloride monotherapy on abnormal lipid control were evaluated in Japanese patients with type 2 diabetes mellitus, comparing with glibenclamide monotherapy. METHODS Patients were randomly assigned to receive, once daily, pioglitazone hydrochloride, at 15 mg or 30 mg (n=46), or glibenclamide, at 1.25 mg or 2.5 mg (n=46). The 24-week study included patients with type 2 diabetes having high levels of triglyceride (TG). RESULTS Pioglitazone hydrochloride produced beneficial effects on dyslipidemia in patients with type 2 diabetes, compared with the baseline and the glibenclamide group, as demonstrated by increases in high-density lipoprotein cholesterol (HDL-C) levels and low-density lipoprotein cholesterol (LDL) particle size, a fall in TG levels, and an increased ratio of visceral to subcutaneous fat volumes (V/S). Pioglitazone hydrochloride reduced fasting serum insulin levels, with low fasting plasma glucose (FPG) and glycohemoglobin levels, compared to the baseline, suggesting an improvement of insulin resistance. CONCLUSION As expected, glibenclamide reduced FPG levels through increased insulin secretion. Pioglitazone hydrochloride and glibenclamide were well tolerated. Pioglitazone hydrochloride improved dyslipidemia related to insulin resistance, whereas glibenclamide enhanced insulin secretion, with only a minor effect on lipid control, in Japanese patients with type 2 diabetes.

[1]  Y. Miyashita,et al.  Clinical determination of the severity of metabolic syndrome: preheparin lipoprotein lipase mass as a new marker of metabolic syndrome. , 2005, Current medicinal chemistry. Cardiovascular and hematological agents.

[2]  P. Scherer,et al.  Erratum: Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes (Diabetes (2004) 53 (1621-1629)) , 2005 .

[3]  P. Scherer,et al.  Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. , 2004, Diabetes.

[4]  L. J. Hardies,et al.  Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.

[5]  A. Festa,et al.  Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  H. Lochnan,et al.  A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. , 2003, Clinical therapeutics.

[7]  F. Ashcroft,et al.  Sulfonylurea stimulation of insulin secretion. , 2002, Diabetes.

[8]  H. Gin,et al.  Oral anti diabetic polychemotherapy in type 2 diabetes mellitus. , 2002, Diabetes & metabolism.

[9]  J. Hardies,et al.  Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.

[10]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[11]  M. Matsuda,et al.  Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.

[12]  T. Saruta,et al.  Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. , 2002, Metabolism: clinical and experimental.

[13]  M. Stumvoll,et al.  Glitazones: clinical effects and molecular mechanisms , 2002, Annals of medicine.

[14]  U. Smith,et al.  Pioglitazone: mechanism of action. , 2001, International journal of clinical practice. Supplement.

[15]  Felicity Kaplan,et al.  PPARs, Insulin Resistance and Type 2 Diabetes , 2001, Journal of cardiovascular risk.

[16]  Wei Chen,et al.  Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. , 2001, Diabetes.

[17]  M. Kipnes,et al.  Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. , 2001, The American journal of medicine.

[18]  S. Halimi,et al.  Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. , 2000, Diabetes care.

[19]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[20]  H. Daida,et al.  Thiazolidinediones, dyslipidaemia and insulin resistance syndrome , 2000, Current opinion in lipidology.

[21]  A. Harrower Comparative Tolerability of Sulphonylureas in Diabetes Mellitus , 2000, Drug safety.

[22]  B. Lowell An Essential Regulator of Adipogenesis and Modulator of Fat Cell Function: PPARγ , 1999, Cell.

[23]  Y. Seino,et al.  Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[24]  R. Krauss,et al.  Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Y. Matsuzawa,et al.  [Insulin resistance syndrome, visceral fat syndrome]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[26]  J. Auwerx,et al.  Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.

[27]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[28]  J. Tugwood,et al.  A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. , 1996, European journal of biochemistry.

[29]  K. Shii,et al.  Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. , 1996, Biochemical and biophysical research communications.

[30]  G. Dagenais,et al.  Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.

[31]  L. N. Kaufman,et al.  Pioglitazone attenuates diet-induced hypertension in rats. , 1995, Metabolism: clinical and experimental.

[32]  M. Laakso,et al.  Lipids and Lipoproteins Predicting Coronary Heart Disease Mortality and Morbidity in Patients With Non-insulin-dependent Diabetes , 1993 .

[33]  J. Friedman,et al.  Tackling a weighty problem , 1992, Cell.

[34]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[35]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[36]  Debbie L. Hahs-Vaughn,et al.  Multiple Comparison Procedures , 2013 .

[37]  L. Grossman New solutions for type 2 diabetes mellitus: the role of pioglitazone. , 2002, PharmacoEconomics.

[38]  P. Suwattee,et al.  Effects of the Thiazolidinediones on Cardiovascular Risk Factors , 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[39]  E. Bonora,et al.  Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin S e n s i t i v i t y , 2000 .

[40]  B. Lowell PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. , 1999, Cell.

[41]  R. Krauss,et al.  Nondenaturing polyacrylamide gradient gel electrophoresis. , 1986, Methods in enzymology.

[42]  Peter Olson,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .